Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer.

ABSTRACT: Prostate cancer (PCa) is the second-most commonly diagnosed cancer in men around the world. It is treated using a risk stratification approach in accordance with the National Comprehensive Cancer Network (NCCN) in the United States. The main treatment options for early PCa include external beam radiation therapy (EBRT), brachytherapy, radical prostatectomy, active surveillance, or a combination approach. In those with advanced disease, androgen deprivation therapy (ADT) is considered as a first-line therapy. However, the majority of cases eventually progress while receiving ADT, leading to castration-resistant prostate cancer (CRPC). The near inevitable progression to CRPC has spurred the recent development of many novel medical treatments using targeted therapies. In this review, we outli

SUBMITTER: Gogola S 

PROVIDER: S-EPMC10000420 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature